Author:
Pavord Ian D.,Hanania Nicola A.,Corren Jonathan
Funder
Teva Pharmaceutical Industries
Genentech
NIHR
Novartis
Eli Lilly and Company
Sanofi
Reference45 articles.
1. Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine;Pavord;J Allergy Clin Immunol Pract,2021
2. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma;Castro;N Engl J Med,2018
3. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials;Castro;Lancet Respir Med,2015
4. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study;Castro;Lancet Respir Med,2014
5. Mepolizumab treatment in patients with severe eosinophilic asthma;Ortega;N Engl J Med,2014
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献